Clinico-pathologic and mammographic characteristics of inflammatory and non-inflammatory breast cancer at six centers in North Africa.


Journal

Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104

Informations de publication

Date de publication:
Jul 2019
Historique:
received: 02 04 2019
accepted: 10 04 2019
pubmed: 23 4 2019
medline: 27 11 2019
entrez: 23 4 2019
Statut: ppublish

Résumé

We describe the clinico-pathologic and mammographic characteristics of inflammatory breast cancer (IBC) and non-IBC cases enrolled in a case-control study. Because IBC is a clinico-pathologic entity with rapid appearance of erythema and other signs, its diagnosis is based on clinical observation and thus, by necessity, subjective. Therefore, we evaluate our cases by photographic review by outside expert clinicians and by degree of adherence to the two most recent definitions of IBC: the international expert panel consensus statement and American Joint Committee on Cancer (AJCC) 8th edition (we used the slightly less restrictive 7th edition definition for our study). We enrolled 267 IBC and 274 age- and geographically matched non-IBC cases at 6 sites in Egypt, Tunisia, and Morocco in a case-control study of IBC conducted between 2009 and 2015. We collected clinico-pathologic and mammographic data and standardized medical photographs of the breast. We identified many differences between IBC and non-IBC cases: 54.5% versus 68.8% were estrogen receptor-positive, 39.9% versus 14.8% human epidermal growth factor receptor 2-positive, 91% versus 4% exhibited erythema, 63% versus 97% had a mass, and 57% versus 10% had mammographic evidence of skin thickening. Seventy-six percent of IBC cases adhered to the expert panel consensus statement and 36% to the AJCC definition; 86 percent were confirmed as IBC by either photographic review or adherence to the consensus statement. We successfully identified distinct groups of IBC and non-IBC cases. The reliability of IBC diagnosis would benefit from expert review of standardized medical photographs and associated clinical information.

Identifiants

pubmed: 31006821
doi: 10.1007/s10549-019-05237-5
pii: 10.1007/s10549-019-05237-5
pmc: PMC6705400
mid: NIHMS1527484
doi:

Substances chimiques

Receptors, Estrogen 0
ERBB2 protein, human EC 2.7.10.1
Receptor, ErbB-2 EC 2.7.10.1

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

407-417

Subventions

Organisme : Intramural NIH HHS
ID : ZIA CP010182-16
Pays : United States
Organisme : NCI NIH HHS
ID : R25 CA112382
Pays : United States

Références

Radiology. 2002 Jun;223(3):829-38
pubmed: 12034956
J Clin Oncol. 2003 Jun 15;21(12):2254-9
pubmed: 12805323
J Natl Cancer Inst. 2005 Jul 6;97(13):966-75
pubmed: 15998949
Clin Breast Cancer. 2005 Dec;6(5):439-45
pubmed: 16381628
Breast Dis. 2005-2006;22:9-23
pubmed: 16735783
Breast Dis. 2005-2006;22:35-44
pubmed: 16735785
Breast Dis. 2005-2006;22:45-54
pubmed: 16735786
J Cancer Educ. 2006 Fall;21(3):169-74
pubmed: 17371184
Breast Cancer Res Treat. 2008 Jun;109(3):417-26
pubmed: 17653852
Ann Oncol. 2008 Mar;19(3):473-80
pubmed: 18006895
Semin Oncol. 2008 Feb;35(1):17-24
pubmed: 18308142
Ann Oncol. 2011 Mar;22(3):515-23
pubmed: 20603440
Breast Cancer Res Treat. 2012 Jan;131(2):437-44
pubmed: 21360074
Clin Breast Cancer. 2012 Aug;12(4):232-9
pubmed: 22694825
Breast Dis. 2011-2012;33(4):159-69
pubmed: 23001584
Cancer Med. 2012 Dec;1(3):338-49
pubmed: 23342283
Cancer Med. 2013 Apr;2(2):178-84
pubmed: 23634285
Cancers (Basel). 2010 Mar 03;2(1):143-52
pubmed: 24281037
Clin Breast Cancer. 2015 Feb;15(1):1-7
pubmed: 25034439
Crit Rev Oncol Hematol. 2015 Feb;93(2):116-26
pubmed: 25459672
Cancer. 1989 Nov 1;64(9):1914-21
pubmed: 2551477
BMC Res Notes. 2017 Mar 16;10(1):126
pubmed: 28302157
PLoS One. 2017 Dec 20;12(12):e0189385
pubmed: 29261724
J Cancer. 2018 Apr 6;9(8):1437-1447
pubmed: 29721054
BMC Cancer. 2018 Jul 5;18(1):713
pubmed: 29976157

Auteurs

Catherine Schairer (C)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. schairec@exchange.nih.gov.
National Cancer Institute, 9609 Medical Center Drive, Rm 6E340, Rockville, MD, 20850, USA. schairec@exchange.nih.gov.

Ahmed Hablas (A)

Gharbiah Cancer Society, Tanta, Egypt.

Ibrahim AbdelBar Seif Eldein (IAS)

Gharbiah Cancer Society, Tanta, Egypt.

Rabab Gaafar (R)

National Cancer Institute, Cairo, Egypt.

Henda Rais (H)

Institute Salah Azaiz, Tunis, Tunisia.

Amel Mezlini (A)

Institute Salah Azaiz, Tunis, Tunisia.

Farhat Ben Ayed (FB)

Association for the Fight Against Cancer, Tunis, Tunisia.

Wided Ben Ayoub (WB)

Institute Salah Azaiz, Tunis, Tunisia.

Abdellatif Benider (A)

Ibn Rochd Oncology Center, Casablanca, Morocco.

Ali Tahri (A)

Clinique Spécialisée Menara, Marrakech, Morocco.

Mouna Khouchani (M)

University Hospital Center Mohammed VI, Marrakech, Morocco.

Dalia Aboulazm (D)

National Cancer Institute, Cairo, Egypt.

Mehdi Karkouri (M)

Ibn Rochd Oncology Center, Casablanca, Morocco.

Saad Eissa (S)

National Cancer Institute, Cairo, Egypt.

Ruth M Pfeiffer (RM)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Shahinaz M Gadalla (SM)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Sandra M Swain (SM)

Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC, USA.

Sofia D Merajver (SD)

University of Michigan, Ann Arbor, MI, USA.

Linda Morris Brown (LM)

RTI International, Rockville, MD, USA.

Amr S Soliman (AS)

Medical School of the City University of New York, New York, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH